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Abstract 
According to the National Health and Nutrition Examination Survey (Nwankwo, Yoon, 
Burt, & Gu, 2013), hypertension affects approximately 70 million Americans and is the most 
commonly treated condition seen in primary care settings in the United States. The cost of 
hypertension on the health care system is estimated to be $46 billion each year, which includes 
services, medications, and missed days from work (Mozzafarian et al., 2015). Furthermore, 
according to the report published by the American Heart Association (AHA) (Mozzafarian et al., 
2015), African Americans make up the largest population of those affected by both controlled 
and uncontrolled hypertension. It is estimated that 43% of African American males, as compared 
to 33.9% of white non-Hispanic American males have hypertension (Mozzafarian et al., 2015). 
In addition, 45.7% of African American women have hypertension, as compared to 31.3% of 
white non-Hispanic American females (Mozzafarian et al., 2015). According to the AHA 
(2014a), African Americans have a higher average blood pressure than non-African Americans. 
They have also been found to develop hypertension and associated complications at an earlier 
age compared to non-African Americans (Mozzafarian et al., 2015). If left uncontrolled, 
hypertension can lead to end target organ damage and death. This creates a burdensome cost to 
the U.S. health care system that may otherwise be avoided with closer screening and control of 
hypertension in all populations.  
This case describes a 48-year-old African American female who presented to the clinic 
for management of her hypertension. Therapy was initiated with lisinopril at a previous office 
visit according to the patient’s medical record. Lisinopril, an angiotensin-converting enzyme 
inhibitor (ACEI), is often used to treat hypertension but it is imperative to consider if this is the 
best treatment for this particular patient using the most current clinical guideline 
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recommendations. The recently released Joint National Committee (JNC 8) guideline 
recommends initiating African Americans with either a thiazide diuretic or calcium channel 
blocker when treating uncomplicated hypertension (James et al., 2014). Therefore, this report 
sought to investigate why differences in hypertension treatment exist between African 
Americans and non-African Americans.  
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Management of Hypertension in African Americans as Compared to Non-African Americans 
       Background 
Hypertension is the most frequently treated condition in primary care settings in the 
United States (Nwankwo, Yoon, Burt, & Gu, 2013). When left uncontrolled, elevated blood 
pressure can lead to complications including myocardial infarction, renal failure, stroke, heart 
failure, or even death (Centers for Disease Control and Prevention, 2015). Patients of African 
ancestry often have more treatment resistant hypertension that results in organ failure and death 
at a faster rate than populations of non-African ancestry (Brewster & Seedat, 2013).  
The gold standard for management of hypertension is the guideline released by the Joint 
National Committee (JNC), which consists of a panel of experts in primary care, cardiology, 
nephrology, hypertension, pharmacology, and evidence-based medicine (James et al., 2014). The 
Eighth Joint National Committee (JNC 8) guideline was published in December 2013. This most 
recent hypertension guideline gives evidenced-based recommendations on treatment thresholds, 
goals, and medications (Armstrong, 2014).  
This case report describes a 48-year-old African American female who presented to the 
clinic for a one-month follow-up after initiating anti-hypertensives. The patient was started on an 
angiotensin-converting enzyme (ACE) inhibitor called lisinopril at 20 mg daily. According to the 
JNC 8 hypertension guideline, lisinopril is not recommended as a first-line medication to treat 
hypertension in African Americans (James et al., 2014). Furthermore, the preferred initial 
treatment for this particular patient with uncomplicated hypertension would be a calcium channel 
blocker (CCB) or a thiazide diuretic (James et al., 2014). Because treatment for hypertension 
varies depending on different patient characteristics, it is important to understand why 
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individuals of certain ethnicities respond differently to treatments and how that ultimately guides 
decision-making as a clinician.   
     Case Report 
Patient Information 
A 48-year-old African American female presented to the clinic for a one-month follow-
up after starting treatment for hypertension. The patient speaks English fluently and is a good 
historian when discussing her medical care. She has no known allergies and is current on all 
immunizations.  
Current Medications 
Four weeks ago, she was started on lisinopril 20 mg by mouth once daily as an initial 
treatment for hypertension. Patient reports that she has been compliant in taking the medication 
as prescribed. Other medications that this patient routinely ingests are women’s daily 
multivitamin and acetaminophen as needed for pain.  
Past Medical and Surgical History 
Hypertension is her only known past medical history and no other co-morbidities. 
Surgical history consists of cholecystectomy and tubal ligation. Family history was not reviewed 
at this clinic appointment.  
Health Presenting Illness 
In addition to lisinopril, the patient has been following the DASH diet (Dietary 
Approaches to Stop Hypertension) as recommended at her previous clinic appointment. She has 
not found it difficult to reduce the amount of sodium in her diet and she has been focusing more 
on foods rich in nutrients such as fruits and vegetables. The patient has also been monitoring her 
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blood pressure at home every morning upon waking and she reports that it averages 140-148 / 
70’s mm Hg.  
Review of Systems 
In addition to following-up on her blood pressure, the patient does report that she has 
noticed a persistent, dry nagging cough that started approximately three to four weeks ago. She 
has not had a recent upper respiratory infection. The patient denies having symptoms of a 
headache, sinus pressure, nasal congestion, dyspnea, shortness of breath, or chest pain. She has 
not noticed any reflux, fatigue, fever, or unexpected weight changes. She denies having 
palpitations, lightheadedness, peripheral edema, rash, muscle cramping, urinary changes, 
abdominal pain or diarrhea.  
Social History 
The patient has no history of tobacco use and no recent exposures. She also denies any 
recent exposure to environmental allergens or irritants. Alcohol use consists of one to two 
glasses of wine four days per week. The patient has never used illicit drugs.  
Physical Examination 
The patient’s blood pressure today is 142/78 mmHg with a heart rate of 72 beats per 
minute. She is smiling, alert and does not appear to be in any acute distress throughout the 
appointment. No abnormal findings were detected with examination of the head, ears, eyes, nose, 
and throat. Upon auscultation of her heart, normal S1, S2 sounds were heard with no rubs, 
gallops, or murmurs. With inspection of the neck, the trachea was midline, no thyromegaly, or 
carotid bruit. The patient’s lungs had symmetrical expansion and clear sounds in all fields. This 
examiner heard a rare dry cough from the patient throughout the assessment. No peripheral 
edema is noted today and the distal pulses are strong, rated +2.  
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Laboratory Testing 
Due to an inability for this examiner to verify if laboratory testing was performed before 
initiating treatment four weeks ago, it would be beneficial to have a complete blood count and 
basic metabolic panel today in order to evaluate her blood components along with liver and 
kidney function. Labs indicate a mildly elevated blood glucose at 120 mg/dL but the patient was 
not fasting prior to the test. In addition, she had a slightly elevated BUN at 28 mg/dL that could 
be indicative of mild dehydration or common side effect of lisinopril. All other laboratory results 
were within the normal expected range for this patient today.  
Assessment, Plan, and Supporting Evidence 
In accordance to the JNC 8 guidelines (James et al., 2014), it is recommended that all 
patients between the ages of 18-60 have a blood pressure goal of less than 140/90 mmHg. 
Additionally, it is recommended that African Americans of any age who are found to have 
elevated blood pressure be started on either on a CCB or thiazide diuretic as long as the patient 
does not have chronic kidney disease (CKD). In the event that an African American patient has 
CKD, then the JNC 8 guideline recommends starting treatment with an angiotensin-converting 
enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) (James et al., 2014). 
Therapeutic lifestyle modifications would also be encouraged along with medication therapy.  
Therefore, in order to provide the patient with individualized and evidence-based care, 
according to the JNC 8 guideline, it was recommended that the patient in this case study stop 
lisinopril and start a thiazide diuretic. According to an article by Allan, Ivers, & Padwal (2012), 
chlorthalidone, a thiazide diuretic, has been shown in several trials to be more effective at 
reducing systolic blood pressure than other commonly used thiazides such as 
hydrochlorothiazide due to its longer half-life. In addition, Allan, Ivers, and Padwal (2012) 
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recommended patients with hypertension be treated with chlorthalidone at 12.5mg daily, which 
can be increased to 25mg to control blood pressure. In regards to the patient in the case study, it 
was recommended she be prescribed chlorthalidone 12.5mg once daily and return to the clinic in 
one month for a follow up visit. If the patient’s blood pressure remained above goal at that time, 
the medication could be increased. Discontinuing the lisinopril will likely eliminate the common 
side effect of a nagging cough, which she has been experiencing (Epocrates, 2016). The patient 
is also encouraged to continue healthy lifestyle modifications such as home monitoring of her 
blood pressure, the DASH diet, increasing activity, and decreasing alcohol intake (American 
Heart Association, 2014).  
Literature Review 
A literature review was performed using the PubMed and CINAHL databases in addition 
to articles retrieved from the Chester Fritz Library. The review was primarily limited to years 
2010 – 2016, but a few outlier articles were included for pertinent background information 
related to the development of JNC guidelines. The purpose of the literature review is to evaluate 
the rationale for separating hypertension treatment by African Americans versus non-African 
Americans as recommended by the JNC 8 guideline.  
JNC 8 Development 
Davis (2015) gives an overview of the JNC 8 recommendations that was released in early 
2014. The development of the JNC 8 is based on the completion of an evidence-based meta-
analysis. The studies were from 1966 to 2009 with a final review of the evidence in 2013 by the 
committee (Davis, 2015). The definition of hypertension remains the same as it did for the JNC 7 
which is a systolic blood pressure greater than 140 mm Hg and diastolic pressure over 90 mm 
Hg. The three questions addressed by the JNC 8 were 1) when to start anti-hypertensives, 2) 
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what is the blood pressure goal to improve outcomes, and 3) which specific drug class should be 
chosen for a specific patient to decrease any undue harm (Davis, 2015). The JNC 8 guideline 
specifies treatment recommendations based on “age, blacks versus non-blacks, presence of 
diabetes or CKD” (James et al., 2014). Under the new guideline, adults less than age 60 should 
be initiated on anti-hypertensives for a systolic blood pressure (SBP) greater than 140 or diastolic 
blood pressure (DBP) greater than 90 mm Hg. For patients over the age of 60, the threshold is 
increased to a SBP 150 mm Hg unless they are in a high-risk category, which would include 
those who are black or who have kidney disease, diabetes, cardiovascular disease, or a history of 
stroke. Patients that have any of these risk factors are recommended to have a blood pressure 
goal of <140/90 mmHg despite their age (Davis, 2015). The seventh recommendation outlined 
by the JNC 8 states that blacks should be initially started with a CCB or thiazide diuretic to treat 
hypertension whether or not they have diabetes. The only exception is blacks that have chronic 
kidney disease, for which the recommended initial treatment is an ACEI or ARB (Davis, 2015). 
The JNC 8 has devised three strategies in the event that the initial medication does not provide 
the preferred outcome. Those strategies are to either maximize the dose of the initial drug before 
adding a second agent from a different class, adding a second agent from a different class and 
then slowly titrating both medications (one at a time), or lastly start with two drugs at once from 
different classes and titrate up before adding a third agent (Davis, 2015). It is of importance to 
note that ACEI and ARBs should not be combined in any of the strategies (Davis, 2015).  
The Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial 
(ALLHAT) was a very large scale, randomized, double-blinded clinical trial that took place from 
1994 through March 2002. Published in 2002, findings indicated that thiazide diuretics were 
superior to CCB and ACEI in several outcomes including heart failure, stroke, and heart attacks 
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specifically for the African American population (Langan & Jones, 2015). Thiazide diuretics had 
improved outcomes for African Americans with and without diabetes. A significant difference in 
the risk for stroke and combined cardiovascular disease was observed when looking at lisinopril 
versus chlorthalidone treatment for African Americans (Furberg et al., 2002). The relative risks 
were in favor of using chlorthalidone, a thiazide diuretic, rather than lisinopril for African 
American patients with hypertension (Furberg et al., 2002). Based on a confidence interval of 
95%, “the relative risks were 1.40 and 1.00 for stroke and 1.19 and 1.06 for combined CVD”  
(Furberg et al., 2002, p.2994). Data from the ALLHAT showed that, although CCB do not 
improve heart failure outcomes as well as thiazides, they are just as effective in anti-hypertension 
management so are also a recommended first line treatment for African American patients 
(Furberg et al., 2002). It is important to note that ALLHAT provided much of the framework 
with which developed the JNC 8.  
Biological Non-Modifiable Differences 
With keeping the JNC 8 recommendations in mind, it is imperative to discuss the 
biological differences between African Americans and non-African Americans that would 
influence the management of hypertension among ethnicities. In other words, what is it about the 
genetic makeup of African Americans that determines a change in the treatment regimen as 
compared to other ethnicities? These biological differences could manifest by an earlier age 
onset of hypertension, more aggressive hypertension disease course, physiological drug response 
to medication, or more resistant hypertension for African Americans. An article published by 
Brewster & Seedat (2013) explains that hypertension in African Americans is “often more 
severe, more resistant to treatment, and leads to earlier end organ damage and premature death” 
as compared to non-African American populations. The CDC (2015) states that high blood 
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pressure increases the risk for life-threatening conditions such as heart attacks, strokes, heart 
failure and kidney disease. Therefore, it is an understanding that organ damage will be seen if 
hypertension develops at an earlier age in African Americans as compared to non-African 
Americans.  
Many potential biomarkers affecting the differential drug response of African Americans 
to anti-hypertensives were discussed in a review by Brewster & Seedat (2013). The authors, 
Brewster & Seedat (2013), performed a systematic review in order to explain why patients of 
African ancestry have better outcomes with CCB and thiazide diuretics as compared to ACEI 
and beta-adrenergic blockers when treating hypertension. The review consisted of 3,763 papers 
including 72 reports that considered the aforementioned classes of drugs. These included 
variations in gene encoding enzymes (specifically cytochrome P450), salt sensitivity, low plasma 
renin activity, and low nitric oxide bioavailability (Brewster & Seedat, 2013). At the time of 
publication, the authors concluded there was no data to explain why patients of African descent 
respond more favorably to certain classes of anti-hypertensives than others.  
Flack, Nasser, & Levy (2011) published an article stating that the renin-angiotensin 
system seems to have an influence on the responsiveness of African Americans to certain classes 
of anti-hypertensives as evidenced by use of diuretics when compared with ACEI. Flack, Nasser, 
& Levy (2011) also postulate that African Americans have lower levels of available nitric oxide 
than non-African Americans, which affects the vascular contractibility. The decreased 
contractibility may require the majority of African Americans to be treated with a combination 
therapy of anti-hypertensives rather than monotherapy due to more resistant hypertension 
according to Flack, Nasser, & Levy (2011). The authors advise that at least one of those drugs in 
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the combination therapy should either be a CCB or thiazide diuretic (Flack, Nasser, & Levy, 
2011).  
An article by Flack et al. (2010) points out that functional and structural abnormalities of 
the vasculature in African Americans has been seen even under normotensive conditions. 
Documented thickening of the intima-media results in increased vessel rigidity along with 
decreased ability to respond under stimuli. If the vasculature is not responding appropriately 
under daily circumstances, then target organ damage may occur (Flack et al., 2010). African 
Americans disproportionately have higher rates of diabetes mellitus and chronic kidney disease 
when combined with hypertension increases their morbidity and mortality (Flack, Nasser, & 
Levy, 2011). The authors mention that, although there have been no determined unique factors in 
the African American populations, there are tendencies that occur that may increase the 
prevalence of hypertension. 
Kaplan and Victor (2010) discussed that the prevalence of hypertension in African 
Americans could be caused by 18 genotype and intermediate phenotype differences. This genetic 
makeup is thought to make this population more sensitive to salt (Kaplan & Victor, 2010). The 
theory hypothesizes that slaves developed an enhanced ability to conserve salt on long ocean 
voyages enabling them to survive conditions causing diarrhea and vomiting. As a result, 
consuming high salt foods increases the blood pressure. Flack et al. (2010) notes that over 50% 
of both “blacks and whites” will exhibit salt sensitivity, which is considered a reversible BP 
phenotype. This manifests as a rise in BP during salt administration or fall in BP with salt 
restriction (Flack, Nasser, & Levy, 2011). The authors suggest that a CCB may be more effective 
at lowering blood pressures with salt-sensitive patients consuming a diet high in salt (Flack et al., 
2010).  
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Advanced age is a risk factor for developing high blood pressure as vessels become more 
rigid contributing to an increased pressure throughout the cardiovascular system (AHA, 2014b). 
As previously stated, African Americans are known to develop hypertension at an earlier age 
when compared to their non-African American counterparts and have higher incidence rates of 
stroke and end-stage renal disease (Harman et al., 2013). The Jackson Heart Study, which was 
published in 2013 by Harman et al., looked at a community-based cohort of 5301 African 
Americans living in Jackson, Mississippi. The authors noted significant control of hypertension 
among this group with thiazide-like diuretics and that CCB showed a lower rate of BP control 
(Harman et al., 2013) in comparison to the thiazides. More data may need to be obtained, as the 
sample taking a CCB was relatively small at 216 during examination1 and then decreased to 122 
subjects by examination 2 (Harman et al., 2013). Nevertheless, it important to keep in mind that 
earlier aggressive treatment may be warranted in African American patients to decrease their risk 
for organ failure, stroke, and death. Williams, Nicholas, Vaziri, & Norris (2014) addresses the 
importance of providers considering multiple factors when treating African American patients 
with hypertension including age, gender, ethnicity, and co-morbidities. Treatment should be 
multi-modal including lifestyle modifications, addressing socioeconomic concerns, and often 
using two or more anti-hypertensive agents. In conclusion, the treatment plan as described by 
Williams, Nicholas, Vaziri, & Norris (2014), “should be guided by individual patient response, 
coexisting risk factors and potential sociocultural considerations such as cost of medications and 
insurance coverage, which affect adherence to both pharmacologic and non-pharmacologic 
interventions”.  
Modifiable Factors 
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According to Flack, Nasser, and Levy (2011), blood pressure control rates are 
significantly lower among the African American populations when compared to other ethnicities. 
This could be multi-factorial rather than just laying blame on the current treatment choice. Those 
factors might include access to care, perceived racism, socioeconomic status, support system, 
knowledge on hypertension, adherence to treatment, substance abuse, mental illness, cultural 
diversity, and obesity (CDC, 2014).  
Obesity is a factor that occurs more commonly among the African American population 
when compared to Caucasian Americans (Flack, Nasser, & Levy, 2011). The extra adipose tissue 
causes a release in cortisol, aldosterone, and is more resistant to anti-hypertensive therapies 
(Redline et al., 1997). Obstructive sleep apnea can be another factor leading to uncontrolled 
hypertension and is often associated with obesity as well. Sleep apnea has been found to be more 
prevalent in the African American population and results in a nocturnal blood pressure that does 
not follow its normal fluctuating pattern (Redline et al., 1997).  
Case Report Learning Points  
• Initial drug therapy in African American patients with uncomplicated 
hypertension is a thiazide diuretic or a calcium channel blocker per the JNC 8 
guidelines 
• Initial drug therapy in African American patients with complicated (chronic 
kidney disease, heart failure, CVA) is an ACEI or ARB per the JNC 8 guidelines 
• African Americans have been shown to develop hypertension at an earlier age that 
is more resistant to treatment. When left uncontrolled, the hypertension has an 
increased risk of target organ failure and death. Due to this, more aggressive is 
MANAGEMENT OF HYPERTENSION IN AFRICAN AMERICANS 
   
16 
recommended such as combination therapy rather than mono-therapy (Flack, 
Nasser, & Levy, 2011). 
• Non-modifiable factors that have been considered to create the difference in 
hypertension and treatment recommendations between African Americans and 
non-African Americans are gene variations leading to salt sensitivity, vascular 
contractibility, renin levels, and nitric oxide availability. 
• Modifiable factors that are prevalent in the African American population include 
health care access, hypertension education, substance abuse, mental illness, 
obesity, OSA, cultural views, poor socioeconomic status, adherence to treatment, 
and perceptions of racism.  
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